{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:58:50Z","timestamp":1783486730577,"version":"3.55.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12020-019-02049-x","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:49:34Z","timestamp":1571140174000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Novel thyroxine formulations: a further step toward precision medicine"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-1950","authenticated-orcid":false,"given":"Camilla","family":"Virili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-4937","authenticated-orcid":false,"given":"Pierpaolo","family":"Trimboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0661-1649","authenticated-orcid":false,"given":"Marco","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/bj0210169","volume":"21","author":"CR Harington","year":"1927","unstructured":"C.R. Harington, G. Barger, Chemistry of thyroxine: constitution and synthesis of thyroxine. Biochem. J. 21, 169\u2013183 (1927)","journal-title":"Biochem. J."},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12020-016-1199-8","volume":"55","author":"JV Hennessey","year":"2017","unstructured":"J.V. Hennessey, The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine 55, 6\u201318 (2017)","journal-title":"Endocrine"},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, American Thyroid Association Task Force on Thyroid Hormone Replacement, Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24, 1670\u20131751 (2014)","journal-title":"Thyroid"},{"key":"2049_CR4","unstructured":"https:\/\/www.statista.com\/statistics\/780284\/levothyroxine-prescriptions-number-in-the-us\/\n                    \n                   Accessed 6 May 2019"},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1208\/s12249-010-9515-8","volume":"11","author":"RB Shah","year":"2010","unstructured":"R.B. Shah, J.S. Collier, V.A. Sayeed, A. Bryant, M.J. Habib, M.A. Khan, Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech 11, 1359\u20131367 (2010)","journal-title":"AAPS PharmSciTech"},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1210\/er.2006-0043","volume":"29","author":"B Biondi","year":"2008","unstructured":"B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29, 76\u2013131 (2008). \n                    https:\/\/doi.org\/10.1210\/er.2006-0043","journal-title":"Endocr. Rev."},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMcp1709318","volume":"378","author":"B Biondi","year":"2018","unstructured":"B. Biondi, D.S. Cooper, Subclinical hyperthyroidism. N. Engl. J. Med. 378, 2411\u20132419 (2018). \n                    https:\/\/doi.org\/10.1056\/NEJMcp1709318","journal-title":"N. Engl. J. Med."},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1210\/er.2013-1083","volume":"35","author":"B Biondi","year":"2014","unstructured":"B. Biondi, L. Wartofsky, Treatment with thyroid hormone. Endocr. Rev. 35, 433\u2013512 (2014). \n                    https:\/\/doi.org\/10.1210\/er.2013-1083","journal-title":"Endocr. Rev."},{"key":"2049_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1210\/jc.2004-1306","volume":"90","author":"F Santini","year":"2005","unstructured":"F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M.G. Castagna, R. Valeriano, M. Giannetti, D. Taddei, R. Centoni, G. Scartabelli, T. Rago, C. Mammoli, R. Elisei, P. Vitti, Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90, 124\u2013127 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2049_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/0004563216642255","volume":"53","author":"V Eligar","year":"2016","unstructured":"V. Eligar, P.N. Taylor, O.E. Okosieme, G.P. Leese, C.M. Dayan, Thyroxine replacement: a clinical endocrinologist\u2019s viewpoint. Ann. Clin. Biochem. 53, 421\u2013433 (2016). \n                    https:\/\/doi.org\/10.1177\/0004563216642255","journal-title":"Ann. Clin. Biochem."},{"key":"2049_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fendo.2018.00699","volume":"9","author":"C Cappelli","year":"2018","unstructured":"C. Cappelli, R. Castello, F. Marini, A. Paoletta, M. Marchetti, M. Saullo, A. Cristiano, I. Pirola, E. Gandossi, A. Ferlin, M. Castellano, Adherence to levothyroxine treatment among patients with hypothyroidism: a Northeastern Italian Survey. Front Endocrinol. 9, 699 (2018). \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00699","journal-title":"Front Endocrinol."},{"key":"2049_CR12","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1089\/thy.2013.0661","volume":"24","author":"HM Robertson","year":"2014","unstructured":"H.M. Robertson, A.K. Narayanaswamy, O. Pereira, S.A. Copland, R. Herriot, A.W. McKinlay, J.S. Bevan, P. Abraham, Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid 24, 1765\u20131771 (2014). \n                    https:\/\/doi.org\/10.1089\/thy.2013.0661","journal-title":"Thyroid"},{"key":"2049_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000452489","volume":"6","author":"N Van Wilder","year":"2017","unstructured":"N. Van Wilder, B. Bravenboer, S. Herremans, N. Vanderbruggen, B. Velkeniers, Pseudomalabsorption of levothyroxine: a challenge for the endocrinologist in the treatment of hypothyroidism. Eur. Thyroid J. 6, 52\u201356 (2017). \n                    https:\/\/doi.org\/10.1159\/000452489","journal-title":"Eur. Thyroid J."},{"key":"2049_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/thy.1991.1.241","volume":"1","author":"MT Hays","year":"1991","unstructured":"M.T. Hays, Localization of human thyroxine absorption. Thyroid 1, 241\u2013248 (1991)","journal-title":"Thyroid"},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.drudis.2013.08.013","volume":"18","author":"SS Jambhekar","year":"2013","unstructured":"S.S. Jambhekar, P.J. Breen, Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov. Today 18, 1173\u20131184 (2013)","journal-title":"Drug Discov. Today"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejpb.2008.10.008","volume":"72","author":"D Pabla","year":"2009","unstructured":"D. Pabla, F. Akhlaghi, H. Zia, A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur. J. Pharm. Biopharm. 72, 105\u2013110 (2009)","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa043903","volume":"354","author":"M Centanni","year":"2006","unstructured":"M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787\u20131795 (2006)","journal-title":"N. Engl. J. Med."},{"key":"2049_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fendo.2017.00092","volume":"8","author":"M Cellini","year":"2017","unstructured":"M. Cellini, M.G. Santaguida, C. Virili, S. Capriello, N. Brusca, L. Gargano, M. Centanni, Hashimoto\u2019s thyroiditis and autoimmune gastritis. Front. Endocrinol. 8, 92 (2017)","journal-title":"Front. Endocrinol."},{"key":"2049_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1210\/er.2018-00168","volume":"40","author":"C Virili","year":"2019","unstructured":"C. Virili, A. Antonelli, M.G. Santaguida, S. Benvenga, M. Centanni, Gastrointestinal malabsorption of thyroxine. Endocr. Rev. 40, 118\u2013136 (2019). \n                    https:\/\/doi.org\/10.1210\/er.2018-00168","journal-title":"Endocr. Rev."},{"key":"2049_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0026-0495(77)90121-4","volume":"26","author":"KW Wenzel","year":"1977","unstructured":"K.W. Wenzel, H.E. Kirschsieper, Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 26, 1\u20138 (1977)","journal-title":"Metabolism"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1210\/jc.2009-0860","volume":"94","author":"TG Bach-Huynh","year":"2009","unstructured":"T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905\u20133912 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2049_CR22","doi-asserted-by":"publisher","unstructured":"A. Tortora, D. La Sala, M. Vitale, Switch from tablet levothyroxine to oral solution resolved reduced absorption by intestinal parasitosis. Endocrinol. Diabetes Metab. Case Rep. \n                    https:\/\/doi.org\/10.1530\/EDM-19-0026","DOI":"10.1530\/EDM-19-0026"},{"key":"2049_CR23","doi-asserted-by":"publisher","first-page":"E419","DOI":"10.1210\/jc.2011-1851","volume":"97","author":"C Virili","year":"2012","unstructured":"C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419\u2013E422 (2012). \n                    https:\/\/doi.org\/10.1210\/jc.2011-1851","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2049_CR24","doi-asserted-by":"publisher","first-page":"E1454","DOI":"10.1210\/jc.2014-1217","volume":"99","author":"M Cellini","year":"2014","unstructured":"M. Cellini, M.G. Santaguida, I. Gatto, C. Virili, S.C. Del Duca, N. Brusca, S. Capriello, L. Gargano, M. Centanni, Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99, E1454\u2013E1458 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-1217","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2049_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12020-014-0509-2","volume":"49","author":"C Virili","year":"2015","unstructured":"C. Virili, M. Centanni, Does microbiota composition affect thyroid homeostasis? Endocrine 49, 583\u2013587 (2015)","journal-title":"Endocrine"},{"key":"2049_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.mce.2017.01.053","volume":"458","author":"C Virili","year":"2017","unstructured":"C. Virili, M. Centanni, \u201cWith a little help from my friends\u201d\u2014the role of microbiota in thyroid hormone metabolism and enterohepatic recycling. Mol. Cell Endocrinol. 458, 39\u201343 (2017)","journal-title":"Mol. Cell Endocrinol."},{"key":"2049_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1590\/S0004-27302010000500002","volume":"54","author":"LS Ward","year":"2010","unstructured":"L.S. Ward, The difficult patient: drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism. Arq. Bras. Endocrinol. Metabol. 54, 435\u2013442 (2010)","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"2049_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40618-017-0706-y","volume":"40","author":"M Centanni","year":"2017","unstructured":"M. Centanni, S. Benvenga, I. Sachmechi, Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J. Endocrinol. Investig. 40, 1289\u20131301 (2017). \n                    https:\/\/doi.org\/10.1007\/s40618-017-0706-y","journal-title":"J. Endocrinol. Investig."},{"key":"2049_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1055\/s-0032-1329951","volume":"62","author":"CS Yue","year":"2012","unstructured":"C.S. Yue, C. Scarsi, M.P. Ducharme, Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 62, 631\u2013636 (2012). \n                    https:\/\/doi.org\/10.1055\/s-0032-1329951","journal-title":"Arzneimittelforschung"},{"key":"2049_CR30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jpeds.2012.11.070","volume":"162","author":"A Cassio","year":"2013","unstructured":"A. Cassio, S. Monti, A. Rizzello, I. Bettocchi, F. Baronio, G. D\u2019Addabbo, M.O. Bal, A. Balsamo, Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J. Pediatr. 162, 1264\u20131269 (2013). \n                    https:\/\/doi.org\/10.1016\/j.jpeds.2012.11.070","journal-title":"J. Pediatr."},{"key":"2049_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000356047","volume":"81","author":"E Peroni","year":"2014","unstructured":"E. Peroni, M.C. Vigone, S. Mora, L.A. Bassi, C. Pozzi, A. Passoni, G. Weber, Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine. Horm. Res. Paediatr. 81, 50\u201354 (2014). \n                    https:\/\/doi.org\/10.1159\/000356047","journal-title":"Horm. Res. Paediatr."},{"key":"2049_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40618-014-0082-9","volume":"37","author":"I Pirola","year":"2014","unstructured":"I. Pirola, L. Daffini, E. Gandossi, D. Lombardi, A. Formenti, M. Castellano, C. Cappelli, Comparison between liquid and tablet levothyroxine formulations in patients treated through enteral feeding tube. J. Endocrinol. Investig. 37, 583\u2013587 (2014). \n                    https:\/\/doi.org\/10.1007\/s40618-014-0082-9","journal-title":"J. Endocrinol. Investig."},{"key":"2049_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/thy.2015.0422","volume":"26","author":"C Cappelli","year":"2016","unstructured":"C. Cappelli, I. Pirola, L. Daffini, A. Formenti, C. Iacobello, A. Cristiano, E. Gandossi, E. Agabiti Rosei, M. Castellano, A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study. Thyroid 26, 197\u2013202 (2016). \n                    https:\/\/doi.org\/10.1089\/thy.2015.0422","journal-title":"Thyroid"},{"key":"2049_CR34","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40618-018-0867-3","volume":"41","author":"I Pirola","year":"2018","unstructured":"I. Pirola, E. Gandossi, D. Brancato, F. Marini, A. Cristiano, A. Delbarba, B. Agosti, M. Castellano, C. Cappelli, TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast. J. Endocrinol. Investig. 41, 1301\u20131306 (2018). \n                    https:\/\/doi.org\/10.1007\/s40618-018-0867-3","journal-title":"J. Endocrinol. Investig."},{"key":"2049_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-015-0788-2","volume":"52","author":"S Morelli","year":"2015","unstructured":"S. Morelli, G. Reboldi, S. Moretti, E. Menicali., N. Avenia., E. Puxeddu, Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation. Endocrine 52, 571\u2013578 (2015). \n                    https:\/\/doi.org\/10.1007\/s12020-015-0788-2","journal-title":"Endocrine"},{"key":"2049_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1871530318666180125155348","volume":"18","author":"R Guglielmi","year":"2018","unstructured":"R. Guglielmi, F. Grimaldi, R. Negro, A. Frasoldati, I. Misischi, F. Graziano, C. Cipri, E. Guastamacchia, V. Triggiani, E. Papini, Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr. Metab. Immune Disord. Drug Targets 18, 235\u2013240 (2018)","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"2049_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1055\/s-0034-1384535","volume":"65","author":"M Giusti","year":"2014","unstructured":"M. Giusti, L. Mortara, N. Machello, E. Monti, G. Pera, M. Marenzana, Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. Drug Res. 65, 332\u2013336 (2014)","journal-title":"Drug Res."},{"key":"2049_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12020-016-1167-3","volume":"57","author":"D Ribichini","year":"2017","unstructured":"D. Ribichini, G. Fiorini, A. Repaci, V. Castelli, L. Gatta, D. Vaira, R. Pasquali, Tablet and oral liquid L-thyroxine formulation in the treatment of na\u00efve hypothyroid patients with Helicobacter pylori infection. Endocrine 57, 394\u2013401 (2017). \n                    https:\/\/doi.org\/10.1007\/s12020-016-1167-3","journal-title":"Endocrine"},{"key":"2049_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12876-016-0439-y","volume":"24","author":"P Fallahi","year":"2016","unstructured":"P. Fallahi, S.M. Ferrari, I. Ruffilli, A. Antonelli, Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. BMC Gastroenterol. 24, 16\u201322 (2016). \n                    https:\/\/doi.org\/10.1186\/s12876-016-0439-y","journal-title":"BMC Gastroenterol."},{"key":"2049_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12020-016-1090-7","volume":"57","author":"P Fallahi","year":"2017","unstructured":"P. Fallahi, S.M. Ferrari, S. Marchi, N. De Bortoli, I. Ruffilli, A. Antonelli, Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine 57, 175\u2013178 (2017). \n                    https:\/\/doi.org\/10.1007\/s12020-016-1090-7","journal-title":"Endocrine"},{"key":"2049_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fendo.2018.00150","volume":"9","author":"S Benvenga","year":"2018","unstructured":"S. Benvenga, G. Capodicasa, S. Perelli, S.M. Ferrari, P. Fallahi, A. Antonelli, Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. Front. Endocrinol. 9, 150 (2018). \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00150","journal-title":"Front. Endocrinol."},{"key":"2049_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/17843286.2016.1196861","volume":"72","author":"C Hommel","year":"2017","unstructured":"C. Hommel, E. Delgrange, Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation? Acta Clin. Belg. 72, 72\u201375 (2017). \n                    https:\/\/doi.org\/10.1080\/17843286.2016.1196861","journal-title":"Acta Clin. Belg."},{"key":"2049_CR43","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s11695-013-1015-y","volume":"23","author":"I Pirola","year":"2013","unstructured":"I. Pirola, A.M. Formenti, E. Gandossi, F. Mittempergher, C. Casella, B. Agosti, C. Cappelli, Oral liquid L-thyroxine (L-T4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes. Surg. 23, 1493\u20131496 (2013). \n                    https:\/\/doi.org\/10.1007\/s11695-013-1015-y","journal-title":"Obes. Surg."},{"key":"2049_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11695-016-2247-4","volume":"27","author":"P Fallahi","year":"2017","unstructured":"P. Fallahi, S.M. Ferrari, S. Camastra, U. Politti, I. Ruffilli, R. Vita, G. Navarra, S. Benvenga, A. Antonelli, TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation. Obes. Surg. 27, 78\u201382 (2017). \n                    https:\/\/doi.org\/10.1007\/s11695-016-2247-4","journal-title":"Obes. Surg."},{"key":"2049_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7861\/clinmedicine.16-5-465","volume":"16","author":"RA Payne","year":"2016","unstructured":"R.A. Payne, The epidemiology of polypharmacy. Clin. Med. 16, 465\u2013469 (2016)","journal-title":"Clin. Med."},{"key":"2049_CR46","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1210\/jc.2014-2684","volume":"99","author":"R Vita","year":"2014","unstructured":"R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481\u20134486 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-2684","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2049_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4158\/EP13418.OR","volume":"20","author":"D Brancato","year":"2014","unstructured":"D. Brancato, A. Scorsone, G. Saura, L. Ferrara, A. Di Noto, V. Aiello, M. Fleres, V. Provenzano, Comparison of TSH levels with liquid formulation versus tablet formulations of levothyroxine in the treatment of adult hypothyroidism. Endocr. Pract. 20, 657\u2013662 (2014). \n                    https:\/\/doi.org\/10.4158\/EP13418.OR","journal-title":"Endocr. Pract."},{"key":"2049_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12020-017-1244-2","volume":"56","author":"S Benvenga","year":"2017","unstructured":"S. Benvenga, F. Di Bari, R. Vita, Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine 56, 138\u2013145 (2017). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1244-2","journal-title":"Endocrine"},{"key":"2049_CR49","doi-asserted-by":"publisher","unstructured":"E. Morini, A. Catalano, A. Lasco, N. Morabito, S. Benvenga, In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. Endocrine. \n                    https:\/\/doi.org\/10.1007\/s12020-019-01908-x\n                    \n                  .","DOI":"10.1007\/s12020-019-01908-x"},{"key":"2049_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17425247.2017.1290604","volume":"14","author":"R Vita","year":"2017","unstructured":"R. Vita, F. Di Bari, S. Benvenga, Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin. Drug Deliv. 14, 467\u2013472 (2017). \n                    https:\/\/doi.org\/10.1080\/17425247.2017.1290604","journal-title":"Expert Opin. Drug Deliv."},{"key":"2049_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12020-017-1242-4","volume":"58","author":"R Ferrara","year":"2017","unstructured":"R. Ferrara, V. Ientile, V. Arcoraci, C. Ferrajolo, C. Piccinni, A. Fontana, S. Benvenga, G. Trifir\u00f2, Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009\u20132015. Endocrine 58, 143\u2013152 (2017). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1242-4","journal-title":"Endocrine"},{"key":"2049_CR52","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eurger.2014.09.006","volume":"5","author":"C Cappelli","year":"2014","unstructured":"C. Cappelli, I. Pirola, L. Daffini, E. Gandossi, B. Agosti, M. Castellano, Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: a single institute survey. Eur. Geriatr. Med. 5, 382\u2013385 (2014)","journal-title":"Eur. Geriatr. Med."},{"key":"2049_CR53","first-page":"1","volume":"20","author":"C Cappelli","year":"2015","unstructured":"C. Cappelli, R. Negro, I. Pirola, E. Gandossi, B. Agosti, M. Castellano, Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol. Endocrinol. 20, 1\u20133 (2015)","journal-title":"Gynecol. Endocrinol."},{"key":"2049_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12020-015-0836-y","volume":"52","author":"P Fallahi","year":"2016","unstructured":"P. Fallahi, S.M. Ferrari, A. Antonelli, Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. Endocrine 52, 597\u2013601 (2016). \n                    https:\/\/doi.org\/10.1007\/s12020-015-0836-y","journal-title":"Endocrine"},{"key":"2049_CR55","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4158\/EP13378.OR","volume":"20","author":"R Negro","year":"2014","unstructured":"R. Negro, R. Valcavi, D. Agrimi, K.A. Toulis, Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients. Endocr. Pract. 20, 901\u2013906 (2014). \n                    https:\/\/doi.org\/10.4158\/EP13378.OR","journal-title":"Endocr. Pract."},{"key":"2049_CR56","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4158\/EP161545.OR","volume":"23","author":"P Fallahi","year":"2017","unstructured":"P. Fallahi, S.M. Ferrari, A. Antonelli, In patients with subclinical hypothyroidism while in therapy with tablet L-T4, the liquid L-T4 formulation is more effective in restoring euthyroidism. Endocr. Pract. 23, 170\u2013174 (2017). \n                    https:\/\/doi.org\/10.4158\/EP161545.OR","journal-title":"Endocr. Pract."},{"key":"2049_CR57","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/lio2.186","volume":"3","author":"P Fallahi","year":"2018","unstructured":"P. Fallahi, S.M. Ferrari, G. Materazzi, F. Ragusa, I. Ruffilli, A. Patrizio, P. Miccoli, A. Antonelli, Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): a prospective study. Laryngoscope Investig. Otolaryngol. 3, 405\u2013408 (2018). \n                    https:\/\/doi.org\/10.1002\/lio2.186","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"2049_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12020-017-1367-5","volume":"60","author":"C Peirce","year":"2018","unstructured":"C. Peirce, S. Ippolito, A. Lanas, M. Pesce, G. Pontieri, D. Arpaia, G. Sarnelli, B. Biondi, Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation. Endocrine 60, 193\u2013196 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1367-5","journal-title":"Endocrine"},{"key":"2049_CR59","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12020-017-1250-4","volume":"58","author":"S Benvenga","year":"2017","unstructured":"S. Benvenga, F.Di Bari, Intestinal absorption and buccal absorption of liquid levothyroxine. Endocrine 58, 591\u2013594 (2017). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1250-4","journal-title":"Endocrine"},{"key":"2049_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fendo.2018.00010","volume":"9","author":"C Virili","year":"2018","unstructured":"C. Virili, L. Giovanella, P. Fallahi, A. Antonelli, M.G. Santaguida, M. Centanni, P. Trimboli, Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front Endocrinol. 9, 10 (2018). \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00010","journal-title":"Front Endocrinol."},{"key":"2049_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12020-018-1574-8","volume":"61","author":"I Laurent","year":"2018","unstructured":"I. Laurent, S. Tang, M. Ast\u00e8re, K.R. Wang, S. Deng, L. Xiao, Q.F. Li, Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine 61, 28\u201335 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-018-1574-8","journal-title":"Endocrine"},{"key":"2049_CR62","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1517\/17425247.2014.918101","volume":"11","author":"R Vita","year":"2014","unstructured":"R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as softgel capsule or liquid solution. Expert Opin. Drug Deliv. 11, 1103\u20131111 (2014)","journal-title":"Expert Opin. Drug Deliv."},{"key":"2049_CR63","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s11739-016-1526-3","volume":"11","author":"G Fiorini","year":"2016","unstructured":"G. Fiorini, D. Ribichini, R. Pasquali, D. Vaira, In vivo dissolution of levothyroxine softgel capsules. Intern. Emerg. Med. 11, 1151\u20131152 (2016)","journal-title":"Intern. Emerg. Med."},{"key":"2049_CR64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/FTD.0b013e318217b69f","volume":"33","author":"P Colucci","year":"2011","unstructured":"P. Colucci, P. D\u2019Angelo, G. Mautone, C. Scarsi, M.P. Ducharme, Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther. Drug Monit. 33, 355\u2013361 (2011). \n                    https:\/\/doi.org\/10.1097\/FTD.0b013e318217b69f","journal-title":"Ther. Drug Monit."},{"key":"2049_CR65","doi-asserted-by":"publisher","first-page":"844","DOI":"10.18433\/J36P5M","volume":"18","author":"C Seng Yue","year":"2015","unstructured":"C. Seng Yue, S. Benvenga, C. Scarsi, L. Loprete, M.P. Ducharme, When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets. J. Pharm. Pharm. Sci. 18, 844\u2013855 (2015)","journal-title":"J. Pharm. Pharm. Sci."},{"key":"2049_CR66","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.4158\/EP13316.CR","volume":"20","author":"R Vita","year":"2014","unstructured":"R. Vita, S. Benvenga, Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in softgel capsule. Endocr. Pract. 20, e38\u2013e41 (2014)","journal-title":"Endocr. Pract."},{"key":"2049_CR67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12020-014-0476-7","volume":"49","author":"MG Santaguida","year":"2015","unstructured":"M.G. Santaguida, C. Virili, S.C. Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49, 51\u201357 (2015). \n                    https:\/\/doi.org\/10.1007\/s12020-014-0476-7","journal-title":"Endocrine"},{"key":"2049_CR68","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12020-017-1311-8","volume":"59","author":"V Di Donna","year":"2018","unstructured":"V. Di Donna, R.M. Paragliola, C. de Waure, G. Papi, A. Pontecorvi, S.M. Corsello, Is levothyroxine requirement the same for tablet and softgel formulations? Endocrine 59, 458\u2013460 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1311-8","journal-title":"Endocrine"},{"key":"2049_CR69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fendo.2017.00321","volume":"8","author":"S Benvenga","year":"2017","unstructured":"S. Benvenga, G. Capodicasa, S. Perelli, l-thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Front. Endocrinol. 8, 321 (2017). \n                    https:\/\/doi.org\/10.3389\/fendo.2017.00321","journal-title":"Front. Endocrinol."},{"key":"2049_CR70","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.4158\/EP14051.CR","volume":"1","author":"PJ Kim","year":"2015","unstructured":"P.J. Kim, I. Sachmechi, Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: effect of intramuscular levothyroxine injections and levothyroxine softgel capsules. AACE Clin. Case Rep. 1, e73\u2013e78 (2015)","journal-title":"AACE Clin. Case Rep."},{"key":"2049_CR71","doi-asserted-by":"publisher","first-page":"1316724","DOI":"10.1155\/2016\/1316724","volume":"2016","author":"DP Reardon","year":"2016","unstructured":"D.P. Reardon, P.S. Yoo, Levothyroxine tablet malabsorption associated with gastroparesis corrected with gelatin capsule formulation. Case Rep. Endocrinol. 2016, 1316724 (2016). \n                    https:\/\/doi.org\/10.1155\/2016\/1316724","journal-title":"Case Rep. Endocrinol."},{"key":"2049_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40268-016-0150-z","volume":"17","author":"FR Ernst","year":"2017","unstructured":"F.R. Ernst, W. Sandulli, R. Elmor, J. Welstead, A.B. Sterman, M. Lavan, Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: results of the CONTROL Switch Study. Drugs R. D. 17, 103\u2013115 (2017). \n                    https:\/\/doi.org\/10.1007\/s40268-016-0150-z","journal-title":"Drugs R. D."},{"key":"2049_CR73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/thy.1995.5.249","volume":"5","author":"S Benvenga","year":"1995","unstructured":"S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5, 249\u2013253 (1995)","journal-title":"Thyroid"},{"key":"2049_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12020-012-9814-9","volume":"43","author":"M Centanni","year":"2013","unstructured":"M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43, 8\u20139 (2013). \n                    https:\/\/doi.org\/10.1007\/s12020-012-9814-9","journal-title":"Endocrine"},{"key":"2049_CR75","doi-asserted-by":"publisher","first-page":"9043450","DOI":"10.1155\/2016\/9043450","volume":"2016","author":"C Cappelli","year":"2016","unstructured":"C. Cappelli, I. Pirola, E. Gandossi, A. Cristiano, L. Daffini, B. Agosti, C. Casella, M. Castellano, Thyroid hormone profile in patients ingesting softgel capsule or liquid levothyroxine formulations with breakfast. Int J. Endocrinol. 2016, 9043450 (2016). \n                    https:\/\/doi.org\/10.1155\/2016\/9043450","journal-title":"Int J. Endocrinol."},{"key":"2049_CR76","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fendo.2018.00118","volume":"9","author":"P Trimboli","year":"2018","unstructured":"P. Trimboli, C. Virili, M. Centanni, L. Giovanella, Thyroxine treatment with softgel capsule formulation: usefulness in hypothyroid patients without malabsorption. Front Endocrinol. 9, 118 (2018). \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00118","journal-title":"Front Endocrinol."},{"key":"2049_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12020012-9772-2","volume":"43","author":"R Vita","year":"2013","unstructured":"R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154\u2013160 (2013). \n                    https:\/\/doi.org\/10.1007\/s12020012-9772-2","journal-title":"Endocrine"},{"key":"2049_CR78","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12020-017-1312-7","volume":"59","author":"E Messina","year":"2018","unstructured":"E. Messina, F. Ferra\u00f9, S. Cannav\u00f2, Oral mucositis induced by treatment with softgel formulation of levothyroxine. Endocrine 59, 226\u2013227 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-017-1312-7","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02049-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:43:16Z","timestamp":1602632596000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02049-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02049-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"3 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"C.V. received reimbursement from Institut Biochimique SA (IBSA) for travel expenses to attend the annual ATA and ETA Meeting. P.T. has nothing to disclose. M.C. received reimbursements from Institut Biochimique SA (IBSA), Pambio Noranco, CH, for travel expenses to attend some international meetings. M.C. received some reimbursement for his participation in advisory boards from Akrimax Pharmaceuticals, Cranford, NY, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As a review article, this paper does not contain any original study with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As a review article, no informed consent is available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}